Trial Profile
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Armodafinil (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Cephalon
- 31 Jul 2021 This trial has been completed in Spain (Global End date: 09 Oct 2013).
- 23 Aug 2018 Status has been changed to discontinued.
- 22 Aug 2013 Planned end date changed from 1 Jul 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.